La Jolla Pharmaceutical (LJPC) Tops Q1 EPS by 9c

La Jolla Pharmaceutical (NASDAQ: LJPC) reported Q1 EPS of ($0.90), $0.09 better than the analyst estimate of ($0.99).

As of June 30, 2016, La Jolla had $100.6 million in cash and cash equivalents, compared to $126.5 million as of December 31, 2015. The decrease in cash and cash equivalents was primarily due to net cash used for operating activities. Based on current operating plans and projections, La Jolla believes that its current cash and cash equivalents are sufficient to fund operations into 2018.

For earnings history and earnings-related data on La Jolla Pharmaceutical (LJPC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Reading (RDI) Tops Q2 EPS by 4c